Evaluation of the Diagnostic Value of the TPD System in Determining ADHF Causing Acute Dyspnea

ADHF Clinical Trial

Official title:

Evaluation of the Diagnostic Value of the TPD System in Determining ADHF Causing Acute Dyspnea

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03998410
• Other study ID #: DOP-27
• Status: Terminated
• Phase: N/A
• Start date: September 15, 2019
• Est. completion date: December 1, 2021

Study information

• Verified date: June 2020
• Source: Echosense Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to evaluate Lung Doppler signals (LDS) among patients presenting to the emergency department with acute dyspnea, in order to determine the diagnostic value of this non-invasive method to discriminate ADHF causing dyspnea from any other cause i.e., non-ADHF causes of dyspnea.

Description:

Dyspnea (shortness of breath) is a common symptom affecting as many as 25% of patients seen in ambulatory settings. It can be caused by many different underlying conditions, some of which arise acutely and can be life-threatening, making rapid clinical evaluation and targeted diagnostic studies of central importance. A number of disorders cause dyspnea, including acute decompensated heart failure (ADHF), chronic obstructive pulmonary disease (COPD), asthma, pulmonary embolism, pneumonia, metabolic acidosis, neuromuscular weakness, and others. The overlapping clinical presentations of these conditions and comorbid diseases can make the diagnostic evaluation of dyspnea a significant challenge.

Acute heart failure (AHF) is a major cause of serious morbidity and death in the general population and one of the most common medical causes of hospitalization among people aged over 60. Patients presenting to the ED with ADHF must be evaluated and treated rapidly to ensure the best possible outcomes. The diagnosis should be made as soon as possible and therapy initiated. Delayed diagnosis at presentation may also result in patients being inappropriately transferred to non-specialist wards, resulting in longer stays, increased re-admission and poorer outcomes. The key to improving the time to diagnosis depends on the clinical evaluation alongside a readiness to initiate relevant additional tests.

Previous studies showed that the TPD has the potential to differentiate between the cardiac cause of dyspnea and any other cause.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 130
• Est. completion date: December 1, 2021
• Est. primary completion date: July 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years

• Patients with acute onset dyspnea (defined as shortness of breath (SOB) at rest or on exertion) and diagnostic uncertainty of etiology where heart failure is in consideration.

• Patients designated to undergo chest X-ray as part of standard of care assessment.

Exclusion Criteria:

• Obvious trauma contributing to dyspnea

• Inability to provide written informed consent

• Not speaking English or Spanish

• Right-sided lobectomy

• Patients with implanted ventricular assist device

• Patient is unable to undergo the TPD test

• Patient is already enrolled in a clinical study with experimental medications

Related Conditions & MeSH terms

• ADHF
• Dyspnea

Intervention

Device:
• Lung Doppler Signals
Recording Doppler ultrasound on the right chest wall

Locations

Country	Name	City	State
United States	The university of Texas Southwestern Medical Center	Dallas	Texas
United States	Wayne State University	Detroit	Michigan
United States	Baylor College of Medicine	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Echosense Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Accuracy of diagnosis	overall accuracy of the TPD system for the determination of ADHF causing acute dyspnea in an ED setting versus the gold standard (GS) diagnosis as determined by the final adjudicated diagnosis	Average of 1 year
Secondary	Sensitivity, Specificity, PPV, NPV of TPD diagnosis	Calculate the analysis success parameters	Average of 1 year